← Back to patent-cliff list
CAS 504-29-0
pyridin-2-amine
Codes：ACAT-013
Application context (from source-drug indications)
套细胞淋巴瘤阿可替尼慢性淋巴细胞白血病阿可替尼淋巴细胞性白血病阿可替尼
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 阿可替尼Acalabrutinib | Tier A — Act now | 2030 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-bromobenzoic acid→pyridin-2-amine→(4-(pyridin-2-ylcarbamoyl)phenyl)boronic acid→3-chloropyrazine-2-carbaldehyde→4-(amino(3-chloropyrazin-2-yl)methyl)-N-(pyridin-2-yl)benzamide→but-2-ynoyl-L-proline
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 2-Butynoic Acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 2-Butynoyl Chloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 3-Chloro-2-pyrazinemethanamine hydrochloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | (S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5 -a]pyrazin-3- yl)pyrrolidine-1-carboxylate Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | [4-[(Pyridin-2-yl)carbamoyl]phenyl]boronic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 4-[8-Amino-3-(2S)-2-pyrrolidinylimidazo[1,5 -a]pyrazin-1-yl]-N-2- pyridinylbenzamide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.